FDA greenlights Protagonist's rusfertide, sold by Takeda as Mimrylo for rare blood cancer
The FDA has approved rusfertide, a weekly injection developed by Protagonist Therapeutics and marketed by Takeda under the name Mimrylo, to treat polycythemia vera.
Regulators gave the go-ahead for rusfertide, a drug created by biotech firm Protagonist Therapeutics. Takeda will commercialize the therapy as Mimrylo. The treatment is administered once a week and is intended for patients with polycythemia vera, a slow-growing blood cancer that causes excess red blood cells and raises the risk of heart attacks, strokes and clots.
Why it matters
It offers the first FDA-approved therapy specifically for polycythemia vera, addressing a serious risk for patients.
In this story
FDArusfertideMimrylopolycythemia verarare blood cancerweekly injectionProtagonist TherapeuticsTakeda
